IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 799 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE here  
     Search
     Current Issue
     Submit Article 
     My Preferences 
     Dermatology crossword 

 


This article has been cited by
1Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs
Sergei A. Grando
International Journal of Dermatology.2019;58(1)114
[DOI]
2Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy
Alessio Buonavoglia,Patrizia Leone,Rosanna Dammacco,Giuseppe Di Lernia,Massimo Petruzzi,Domenico Bonamonte,Angelo Vacca,Vito Racanelli,Franco Dammacco
Autoimmunity Reviews.2019;18(4)349
[DOI]
3Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus
Soheil Tavakolpour
Dermatologic Therapy.2018;31(5)e12696
[DOI]
4Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges
Soheil Tavakolpour
Immunology Letters.2017;190(5)130
[DOI]
5Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up
Vinod K. Sharma,Vishal Gupta,Neetu Bhari,Vishwajeet Singh
International Journal of Dermatology.2020;59(1)76
[DOI]
6Rituximab: A Review in Pemphigus Vulgaris
James E. Frampton
American Journal of Clinical Dermatology.2020;21(1)149
[DOI]
7Pemphigus: Current and Future Therapeutic Strategies
Dario Didona,Roberto Maglie,Rüdiger Eming,Michael Hertl
Frontiers in Immunology.2019;10(1)149
[DOI]
8Rituximab in the treatment of pemphigus
Shawn Shetty,A. Razzaque Ahmed
Expert Opinion on Orphan Drugs.2017;5(1)99
[DOI]
9Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases
Hamidreza Mahmoudi,Kamran Balighi,Soheil Tavakolpour,Maryam Daneshpazhooh
International Immunopharmacology.2019;71(1)40
[DOI]
10Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine
HamidReza Mahmoudi,Elaheh Ebrahimi,Maryam Daneshpazhooh,Kamran Balighi,Azin Mirzazadeh,Somayeh Elikaei Behjati,Soheil Tavakolpour
International Journal of Immunogenetics.2020;47(1)41
[DOI]
11Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus
Soheil Tavakolpour
Archives of Dermatological Research.2018;310(2)95
[DOI]
12Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review
Soheil Tavakolpour,HamidReza Mahmoudi,Kamran Balighi,Robabeh Abedini,Maryam Daneshpazhooh
International Immunopharmacology.2018;54(2)131
[DOI]
13Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases
Aniek Lamberts,H. Ilona Euverman,Jorrit B. Terra,Marcel F. Jonkman,Barbara Horváth
Frontiers in Immunology.2018;9(2)131
[DOI]
14Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Kamran Balighi,Maryam Daneshpazhooh,HamidReza Mahmoudi,Mehrnoosh Badakhsh,Amir Teimourpour,Amir Houshang Ehsani,Arghavan Azizpour,Zahra Akbari,Mostafa Mahdavinia,Mojtaba Ghasemiadl,Soheil Tavakolpour
Archives of Dermatological Research.2019;311(1)63
[DOI]
15Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
Soheil Tavakolpour
International Immunopharmacology.2017;53(1)133
[DOI]
16The role of flavonoids in autoimmune diseases: Therapeutic updates
Kannan R.R. Rengasamy,Haroon Khan,Shanmugaraj Gowrishankar,Ricardo J.L. Lagoa,Fawzi M. Mahomoodally,Ziyad Khan,Shanoo Suroowan,Devesh Tewari,Gokhan Zengin,Sherif T.S. Hassan,Shunmugiah Karutha Pandian
Pharmacology & Therapeutics.2019;194(1)107
[DOI]
Online since 15th March '04
Published by Wolters Kluwer - Medknow